{
    "nctId": "NCT00090844",
    "briefTitle": "Triptorelin for Preserving Ovarian Function in Premenopausal Women Receiving Chemotherapy for Early-Stage Breast Cancer",
    "officialTitle": "Preservation of Ovarian Function in Young Women Treated With (Neo) Adjuvant Chemotherapy for Breast Cancer: A Randomized Trial Using the Gonadotropin-releasing Hormone (GnRH) Agonist (Triptorelin) During Chemotherapy",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer, Hormone Changes, Drug Toxicity",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 49,
    "primaryOutcomeMeasure": "Time to Resumption of Menses",
    "eligibilityCriteria": "Inclusion Criteria:\n\nDISEASE CHARACTERISTICS:\n\n* Histologically confirmed breast cancer\n\n  * Early-stage, operable disease\n* Scheduled to receive adjuvant or neoadjuvant systemic chemotherapy for breast cancer\n* Hormone receptor status:\n\n  * Meets 1 of the following criteria:\n\n    * Estrogen receptor (ER)- OR progesterone receptor (PR)-positive\n    * ER- AND PR-negative\n* No history of premature ovarian failure\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* Under 45\n\nSex\n\n* Female\n\nMenopausal status\n\n* Premenopausal\n\n  * Follicle-stimulating hormone levels \\< 40 IU/L at baseline AND at least 2 menstrual periods within the past 6 months\n* No first-degree relative menopausal at \\< 40 years of age\n\nPerformance status\n\n* Eastern Cooperative Oncology Group \\[ECOG\\] 0-1\n\nLife expectancy\n\n* Not specified\n\nHematopoietic\n\n* Not specified\n\nHepatic\n\n* Not specified\n\nRenal\n\n* Not specified\n\nOther\n\n* Not pregnant or nursing\n* Fertile patients must use effective non-hormonal methods of contraception\n* No prior osteoporosis or other non-malignant systemic disease that would preclude prolonged follow-up\n* No known allergies to gonadotrophin-releasing hormone agonists\n* No other cancer except nonmelanoma skin cancer\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* Not specified\n\nChemotherapy\n\n* See Disease Characteristics\n* No prior chemotherapy\n\nEndocrine therapy\n\n* At least 2 weeks since prior oral contraceptives\n* No prior fertility treatment\n\n  * Clomiphene or pergonal for polycystic ovarian disease allowed\n* No other concurrent oral or transdermal hormonal therapy, including any of the following:\n\n  * Estrogen\n  * Progesterone\n  * Androgens\n  * Aromatase inhibitors\n  * Hormone replacement therapy\n  * Oral contraceptives\n\nRadiotherapy\n\n* No prior ovarian radiotherapy\n\nSurgery\n\n* No prior bilateral oophorectomy\n* No plans for oophorectomy or hysterectomy within the next 2 years\n\nOther\n\n* At least 1 week since prior warfarin\n\nExclusion Criteria:\n\n* History of premature ovarian failure\n* Over 45 years of age\n* First-degree relative menopausal at \\< 40 years of age\n* Pregnant or nursing\n* Prior osteoporosis or other non-malignant systemic disease that would preclude prolonged follow-up\n* Known allergies to gonadotrophin-releasing hormone agonists\n* Other cancer besides nonmelanoma skin cancer\n* Prior chemotherapy\n* Prior ovarian radiotherapy\n* Prior bilateral oophorectomy",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT"
}